Moleculin Biotech Stock Price, News & Analysis (NASDAQ:MBRX)

$1.90 0.05 (2.70 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$1.85
Today's Range$1.82 - $1.92
52-Week Range$0.71 - $3.75
Volume354,204 shs
Average Volume174,043 shs
Market Capitalization$40.16 million
P/E Ratio-4.04
Dividend YieldN/A
BetaN/A

About Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.

Receive MBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:MBRX
CUSIPN/A
Phone+1-713-3005160

Debt

Debt-to-Equity RatioN/A
Current Ratio5.17%
Quick Ratio5.17%

Price-To-Earnings

Trailing P/E Ratio-4.04255319148936
Forward P/E Ratio-4.04
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.23 per share
Price / Book1.54

Profitability

Trailing EPS($0.47)
Net Income$-3,920,000.00
Net MarginsN/A
Return on Equity-40.84%
Return on Assets-35.87%

Miscellaneous

Employees6
Outstanding Shares21,140,000

Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech Inc (NASDAQ:MBRX) posted its earnings results on Tuesday, November, 14th. The company reported ($0.14) earnings per share for the quarter. View Moleculin Biotech's Earnings History.

When will Moleculin Biotech make its next earnings announcement?

Moleculin Biotech is scheduled to release their next quarterly earnings announcement on Monday, April, 2nd 2018. View Earnings Estimates for Moleculin Biotech.

Where is Moleculin Biotech's stock going? Where will Moleculin Biotech's stock price be in 2018?

1 brokerages have issued twelve-month target prices for Moleculin Biotech's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Moleculin Biotech's stock price to reach $8.00 in the next year. View Analyst Ratings for Moleculin Biotech.

Who are some of Moleculin Biotech's key competitors?

How do I buy Moleculin Biotech stock?

Shares of Moleculin Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Moleculin Biotech's stock price today?

One share of Moleculin Biotech stock can currently be purchased for approximately $1.90.

How big of a company is Moleculin Biotech?

Moleculin Biotech has a market capitalization of $40.16 million. The company earns $-3,920,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Moleculin Biotech employs 6 workers across the globe.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 2575 W Bellfort Ave Ste 333, HOUSTON, TX 77054-5025, United States. The company can be reached via phone at +1-713-3005160.


MarketBeat Community Rating for Moleculin Biotech (MBRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  97
MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Moleculin Biotech (NASDAQ:MBRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00N/AN/A
Price Target Upside: 373.37% upside373.37% upsideN/AN/A

Moleculin Biotech (NASDAQ:MBRX) Consensus Price Target History

Price Target History for Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech (NASDAQ:MBRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/20/2017Roth CapitalInitiated CoverageBuy -> Buy$8.00HighView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Moleculin Biotech (NASDAQ:MBRX) Earnings History and Estimates Chart

Earnings by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech (NASDAQ MBRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/2/2018N/AView Earnings Details
11/14/2017Q3 2017($0.14)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.19)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.02)ViewN/AView Earnings Details
4/3/2017Q4 2016($0.12)ViewN/AView Earnings Details
11/21/2016Q316($0.12)ViewN/AView Earnings Details
8/15/2016Q2 2016($0.11)ViewN/AView Earnings Details
6/16/2016Q1 2016($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Moleculin Biotech (NASDAQ:MBRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.47 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS

Dividends

Dividend History for Moleculin Biotech (NASDAQ:MBRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Moleculin Biotech (NASDAQ MBRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 20.80%
Institutional Ownership Percentage: 3.09%
Insider Trades by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech (NASDAQ MBRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2017Waldemar PriebeMajor ShareholderSell100,000$1.70$170,000.00View SEC Filing  
5/11/2017Walter V. KlempCEOBuy12,000$0.81$9,720.00View SEC Filing  
5/5/2017Jacqueline NorthcutDirectorBuy1,000$0.82$820.001,000View SEC Filing  
4/28/2017Robert E GeorgeDirectorBuy1,000$0.94$940.001,000View SEC Filing  
4/25/2017Jonathan P FosterInsiderBuy10,000$0.86$8,600.0010,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Moleculin Biotech (NASDAQ MBRX) News Headlines

Source:
DateHeadline
Leading Leukemia Experts Join Moleculins Science Advisory BoardLeading Leukemia Experts Join Moleculin's Science Advisory Board
finance.yahoo.com - January 17 at 9:01 AM
Moleculin Biotech (MBRX) Announces Development Pipeline Expansion with Immuno-Stimulating STAT3 InhibitorMoleculin Biotech (MBRX) Announces Development Pipeline Expansion with Immuno-Stimulating STAT3 Inhibitor
www.streetinsider.com - January 11 at 9:29 AM
Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 InhibitorMoleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor
finance.yahoo.com - January 10 at 9:17 AM
Moleculin Biotech (MBRX) Reports Polish Approval for Leukemia Clinical TrialMoleculin Biotech (MBRX) Reports Polish Approval for Leukemia Clinical Trial
www.streetinsider.com - December 23 at 6:08 AM
Moleculin Biotech (MBRX) Reports Polish Approval for Leukemia ... - StreetInsider.comMoleculin Biotech (MBRX) Reports Polish Approval for Leukemia ... - StreetInsider.com
www.streetinsider.com - December 22 at 9:21 AM
Moleculin Announces Polish Approval for Leukemia Clinical TrialMoleculin Announces Polish Approval for Leukemia Clinical Trial
finance.yahoo.com - December 21 at 9:11 AM
Moleculin Biotech (MBRX) Receives New Coverage from Analysts at Roth CapitalMoleculin Biotech (MBRX) Receives New Coverage from Analysts at Roth Capital
www.americanbankingnews.com - December 20 at 10:40 AM
Moleculin Biotech (MBRX) Secures $2M Private Grant for WP1066 DrugMoleculin Biotech (MBRX) Secures $2M Private Grant for WP1066 Drug
www.streetinsider.com - December 7 at 9:15 AM
Moleculins WP1066 Drug receives $2 million Private GrantMoleculin's WP1066 Drug receives $2 million Private Grant
finance.yahoo.com - December 6 at 5:37 PM
Mid-Afternoon Market Update: Francescas Drops On Earnings Miss; Revance Therapeutics Shares Gain - BenzingaMid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain - Benzinga
www.benzinga.com - December 5 at 5:31 PM
Mid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide - BenzingaMid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide - Benzinga
www.benzinga.com - December 5 at 5:31 PM
Moleculins WP1066 Drug gets FDA Brain Tumor IND ClearanceMoleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance
finance.yahoo.com - December 5 at 9:52 AM
Why Moleculin Biotech Inc’s (MBRX) Ownership Structure Is ImportantWhy Moleculin Biotech Inc’s (MBRX) Ownership Structure Is Important
finance.yahoo.com - November 28 at 5:34 PM
Moleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PTMoleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PT
finance.yahoo.com - November 22 at 2:53 AM
Moleculin Biotech, Inc. (MBRX) Announces Quarterly  Earnings ResultsMoleculin Biotech, Inc. (MBRX) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 15 at 1:13 PM
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
finance.yahoo.com - November 15 at 6:12 AM
Moleculin Biotech, Inc. (MBRX) Set to Announce Earnings on MondayMoleculin Biotech, Inc. (MBRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - November 13 at 2:08 AM
Moleculin Appoints Dr. Sandra Silberman as Chief Medical Officer -- New ProductsMoleculin Appoints Dr. Sandra Silberman as Chief Medical Officer -- New Products
finance.yahoo.com - November 8 at 4:56 PM
Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain TumorsMoleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors
finance.yahoo.com - November 2 at 6:14 AM
Moleculin Requests Authorization from the Polish Government to Advance AnnamycinMoleculin Requests Authorization from the Polish Government to Advance Annamycin
finance.yahoo.com - October 25 at 7:01 AM
Moleculin Requests Authorization from the Polish Government to Advance AnnamycinMoleculin Requests Authorization from the Polish Government to Advance Annamycin
finance.yahoo.com - October 25 at 7:01 AM
Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin TrialMoleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial
finance.yahoo.com - October 19 at 6:08 AM
Moleculin Announces Strategic Collaboration to Develop Immune Stimulation DrugMoleculin Announces Strategic Collaboration to Develop Immune Stimulation Drug
finance.yahoo.com - October 11 at 3:19 PM
Corporate News Blog - Moleculin Biotech Signs Agreement with the First Hospital to Conduct Clinical Trials for AnnamycinCorporate News Blog - Moleculin Biotech Signs Agreement with the First Hospital to Conduct Clinical Trials for Annamycin
finance.yahoo.com - October 6 at 10:16 AM
Moleculin Signs Agreement with First Hospital for Annamycin TrialsMoleculin Signs Agreement with First Hospital for Annamycin Trials
finance.yahoo.com - October 4 at 6:47 AM
Moleculin Announces FDA Approval of Annamycin INDMoleculin Announces FDA Approval of Annamycin IND
finance.yahoo.com - October 2 at 12:02 PM
Todays Research Reports on Stocks to Watch: Axovant and MoleculinToday's Research Reports on Stocks to Watch: Axovant and Moleculin
finance.yahoo.com - October 2 at 12:02 PM
Corporate News Blog - FDA Grants Approval to Moleculin Biotech for Clinical Trials of Annamycin in the Treatment of AMLCorporate News Blog - FDA Grants Approval to Moleculin Biotech for Clinical Trials of Annamycin in the Treatment of AML
finance.yahoo.com - October 2 at 12:02 PM
Moleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell LymphomaMoleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell Lymphoma
finance.yahoo.com - September 14 at 7:29 AM
Moleculin to Collaborate on Combining its WP1122 Brain Cancer Drug Candidate with Roches Drug AvastinMoleculin to Collaborate on Combining its WP1122 Brain Cancer Drug Candidate with Roche's Drug Avastin
finance.yahoo.com - September 7 at 1:01 AM
Moleculin Announces Participation at the 19th Annual Rodman & Renshaw Global Investment ConferenceMoleculin Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 1 at 3:32 AM
Moleculin Announces Filing with FDA of IND for its Leukemia Drug AnnamycinMoleculin Announces Filing with FDA of IND for its Leukemia Drug Annamycin
finance.yahoo.com - August 30 at 6:23 AM
Moleculin to meet with EMA on trial design for AML candidate AnnamycinMoleculin to meet with EMA on trial design for AML candidate Annamycin
seekingalpha.com - August 24 at 9:01 AM
Corporate News Blog - Moleculin Biotech to Meet European Medicines Agency; Discussion on Clinical Trial Authorization for the Treatment of Acute Myeloid LeukemiaCorporate News Blog - Moleculin Biotech to Meet European Medicines Agency; Discussion on Clinical Trial Authorization for the Treatment of Acute Myeloid Leukemia
finance.yahoo.com - August 24 at 9:01 AM
Moleculin Announces Meeting with European Medicines AgencyMoleculin Announces Meeting with European Medicines Agency
finance.yahoo.com - August 22 at 8:48 PM
Moleculin Biotech, Inc. (MBRX) Major Shareholder Waldemar Priebe Sells 100,000 SharesMoleculin Biotech, Inc. (MBRX) Major Shareholder Waldemar Priebe Sells 100,000 Shares
www.americanbankingnews.com - August 18 at 8:32 PM
Biotech Sector Rises on Accelerated Anti-cancer Drug Candidate Developments and Clinical Trial ProgressBiotech Sector Rises on Accelerated Anti-cancer Drug Candidate Developments and Clinical Trial Progress
www.prnewswire.com - August 18 at 8:18 PM
Moleculin Biotech (MBRX) Buys Active Drug Compound for Treatment of Brain CancerMoleculin Biotech (MBRX) Buys Active Drug Compound for Treatment of Brain Cancer
www.streetinsider.com - August 17 at 2:06 AM
Moleculin Acquires Active Drug Compound for the Treatment of Brain CancerMoleculin Acquires Active Drug Compound for the Treatment of Brain Cancer
finance.yahoo.com - August 17 at 2:06 AM
Moleculin Biotech, Inc. (MBRX) Issues  Earnings ResultsMoleculin Biotech, Inc. (MBRX) Issues Earnings Results
www.americanbankingnews.com - August 15 at 12:46 PM
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017
finance.yahoo.com - August 15 at 1:19 AM
Moleculin Updates Annamycin Progress, Analyst Coverage, Price Target and Full Pipeline ReviewMoleculin Updates Annamycin Progress, Analyst Coverage, Price Target and Full Pipeline Review
finance.yahoo.com - August 15 at 1:19 AM
Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Significant Increase in Short InterestMoleculin Biotech, Inc. (NASDAQ:MBRX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - August 13 at 1:46 AM
Moleculin Comments on Recent FDA Drug Approvals for Acute Myeloid LeukemiaMoleculin Comments on Recent FDA Drug Approvals for Acute Myeloid Leukemia
finance.yahoo.com - August 10 at 4:40 AM
Moleculin Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CROMoleculin Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CRO
finance.yahoo.com - August 4 at 1:18 AM
Moleculin Biotech, Inc. (MBRX) Short Interest UpdateMoleculin Biotech, Inc. (MBRX) Short Interest Update
www.americanbankingnews.com - July 28 at 1:46 AM
Moleculins New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer CenterMoleculin's New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer Center
finance.yahoo.com - July 25 at 11:32 PM
Featured Company News - Moleculin Biotech Signs License Agreement with MD Anderson Cancer Center for its Lead Product Candidate, AnnamycinFeatured Company News - Moleculin Biotech Signs License Agreement with MD Anderson Cancer Center for its Lead Product Candidate, Annamycin
finance.yahoo.com - July 21 at 2:03 AM
Moleculin Biotech (MBRX) Reports Agreement with MD Anderson Cancer Center for Leukemia Drug, AnnamycinMoleculin Biotech (MBRX) Reports Agreement with MD Anderson Cancer Center for Leukemia Drug, Annamycin
www.streetinsider.com - July 18 at 11:09 PM
Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Up 250.7% in JuneMoleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Up 250.7% in June
www.americanbankingnews.com - July 15 at 7:22 AM

SEC Filings

Moleculin Biotech (NASDAQ:MBRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Moleculin Biotech (NASDAQ:MBRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Moleculin Biotech (NASDAQ MBRX) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.